高 MCM6 表达可作为透明细胞肾细胞癌的一种潜在预后标志物。
High MCM6 Expression as a Potential Prognostic Marker in Clear-cell Renal Cell Carcinoma.
机构信息
Department of Pathology, Yeungnam University College of Medicine, Gyeongsan, Republic of Korea.
Department of Urology, Yeungnam University College of Medicine, Gyeongsan, Republic of Korea.
出版信息
In Vivo. 2021 Jan-Feb;35(1):299-306. doi: 10.21873/invivo.12259.
Abstract
AIM
Minichromosome maintenance (MCM) proteins are involved in initiation of DNA replication and cell-cycle progression. Loss of MCM function results in genomic instability and causes carcinogenesis. Among MCM genes, the role and prognostic value of MCM6 expression in clear-cell renal cell carcinoma (ccRCC) has not been elucidated.
MATERIALS AND METHODS
We assessed the mRNA expression level of MCM6 using the Gene Expression Profiling Interactive Analysis database and investigated MCM6 protein expression by immunohistochemistry in 238 ccRCC cases.
RESULTS
High MCM6 expression was significantly associated with increasing tumor size, pT, stage, tumor necrosis, and metastasis. Furthermore, high MCM6 expression was significantly associated with shorter overall and disease-free survival, and was an independent unfavorable prognostic marker. Regarding patients with metastasis, high MCM6-expressing ccRCC conferred significantly shorter survival than for those with low expression.
CONCLUSION
A high MCM6 expression level may be a promising biomarker to predict tumor progression, metastasis, and survival in patients with ccRCC.
摘要
目的
微小染色体维持（MCM）蛋白参与 DNA 复制的起始和细胞周期进程。MCM 功能的丧失会导致基因组不稳定并引发致癌作用。在 MCM 基因中，MCM6 表达在透明细胞肾细胞癌（ccRCC）中的作用和预后价值尚未阐明。
材料和方法
我们使用基因表达谱交互分析数据库评估了 MCM6 的 mRNA 表达水平，并通过免疫组织化学方法在 238 例 ccRCC 病例中检测了 MCM6 蛋白的表达。
结果
高 MCM6 表达与肿瘤大小增加、pT、分期、肿瘤坏死和转移显著相关。此外，高 MCM6 表达与总生存期和无病生存期缩短显著相关，是独立的不利预后标志物。对于发生转移的患者，高 MCM6 表达的 ccRCC 患者的生存时间明显短于低表达的患者。
结论
MCM6 高表达水平可能是预测 ccRCC 患者肿瘤进展、转移和生存的有前途的生物标志物。
相似文献
1
High MCM6 Expression as a Potential Prognostic Marker in Clear-cell Renal Cell Carcinoma.高 MCM6 表达可作为透明细胞肾细胞癌的一种潜在预后标志物。
In Vivo. 2021 Jan-Feb;35(1):299-306. doi: 10.21873/invivo.12259.
2
FCER1G positively relates to macrophage infiltration in clear cell renal cell carcinoma and contributes to unfavorable prognosis by regulating tumor immunity.FCER1G 与透明细胞肾细胞癌中的巨噬细胞浸润呈正相关，并通过调节肿瘤免疫来影响不良预后。
BMC Cancer. 2022 Feb 4;22(1):140. doi: 10.1186/s12885-022-09251-7.
3
MCM6 promotes metastasis of hepatocellular carcinoma via MEK/ERK pathway and serves as a novel serum biomarker for early recurrence.MCM6 通过 MEK/ERK 通路促进肝细胞癌的转移，并作为早期复发的新型血清生物标志物。
J Exp Clin Cancer Res. 2018 Jan 22;37(1):10. doi: 10.1186/s13046-017-0669-z.
4
MCM6 promotes intrahepatic cholangiocarcinoma progression by upregulating E2F1 and enhancing epithelial-mesenchymal transition.MCM6 通过上调 E2F1 和增强上皮-间充质转化促进肝内胆管癌的进展。
Carcinogenesis. 2023 Jun 24;44(4):279-290. doi: 10.1093/carcin/bgad023.
5
Minichromosome maintenance complex component 6 (MCM6) expression correlates with histological grade and survival in endometrioid endometrial adenocarcinoma.MCM6 在子宫内膜样腺癌中的表达与组织学分级和生存相关。
Virchows Arch. 2018 Apr;472(4):623-633. doi: 10.1007/s00428-017-2278-9. Epub 2017 Dec 14.
6
MCM family in HCC: MCM6 indicates adverse tumor features and poor outcomes and promotes S/G2 cell cycle progression.MCM 家族在 HCC 中的作用：MCM6 预示着不良的肿瘤特征和预后不良，并促进 S/G2 细胞周期进程。
BMC Cancer. 2018 Feb 20;18(1):200. doi: 10.1186/s12885-018-4056-8.
7
Prognostic implications of Aquaporin 9 expression in clear cell renal cell carcinoma.水通道蛋白 9 表达对肾透明细胞癌预后的影响。
J Transl Med. 2019 Nov 8;17(1):363. doi: 10.1186/s12967-019-2113-y.
8
Overexpression of MCM6 predicts poor survival in patients with glioma.MCM6 过表达预示着胶质瘤患者的生存不良。
Hum Pathol. 2018 Aug;78:182-187. doi: 10.1016/j.humpath.2018.04.024. Epub 2018 May 9.
9
MCM6 is a Poor Prognostic Biomarker and Promotes Progression in Breast Cancer.MCM6 是一种预后不良的生物标志物，并促进乳腺癌的进展。
Front Biosci (Landmark Ed). 2023 Aug 30;28(8):128. doi: 10.31083/j.fbl2808188.
10
Integrating HECW1 expression into the clinical indicators exhibits high accuracy in assessing the prognosis of patients with clear cell renal cell carcinoma.将 HECW1 表达纳入临床指标可高度准确地评估透明细胞肾细胞癌患者的预后。
BMC Cancer. 2021 Aug 4;21(1):890. doi: 10.1186/s12885-021-08631-9.
引用本文的文献
1
Prognostic markers in pheochromocytomas/paragangliomas: the role of histopathology, SDHB, MAML3 and MCM6 expression.嗜铬细胞瘤/副神经节瘤的预后标志物：组织病理学、SDHB、MAML3和MCM6表达的作用
J Endocrinol Invest. 2025 May 30. doi: 10.1007/s40618-025-02610-8.
2
Biophysical investigation of the molecular interaction between minichromosome maintenance protein 6 and Bloom syndrome helicase.微小染色体维持蛋白6与布卢姆综合征解旋酶之间分子相互作用的生物物理研究。
FEBS J. 2025 Jun;292(12):3151-3164. doi: 10.1111/febs.70047. Epub 2025 Feb 25.
3
Construction and experimental verification of a novel nine-glycosylation-related gene prognostic risk model for clear cell renal carcinoma.一种用于透明细胞肾细胞癌的新型九糖基化相关基因预后风险模型的构建与实验验证。
Heliyon. 2024 Oct 11;10(21):e39258. doi: 10.1016/j.heliyon.2024.e39258. eCollection 2024 Nov 15.
4
LncRNA LINC00667 gets involved in clear cell renal cell carcinoma development and chemoresistance by regulating the miR-143-3p/ZEB1 axis.长链非编码 RNA LINC00667 通过调控 miR-143-3p/ZEB1 轴参与肾透明细胞癌的发生发展及化疗耐药。
Aging (Albany NY). 2023 Oct 11;15(19):10057-10071. doi: 10.18632/aging.205029.
5
Systematic analysis of expression and prognostic significance for MCM family in head and neck squamous cell carcinoma.系统分析 MCM 家族在头颈部鳞状细胞癌中的表达及预后意义。
Histol Histopathol. 2024 Apr;39(4):471-482. doi: 10.14670/HH-18-652. Epub 2023 Jul 24.
6
DNA replication: Mechanisms and therapeutic interventions for diseases.DNA复制：疾病的机制与治疗干预措施
MedComm (2020). 2023 Feb 5;4(1):e210. doi: 10.1002/mco2.210. eCollection 2023 Feb.
7
A Novel Prognostic Signature Associated With the Tumor Microenvironment in Kidney Renal Clear Cell Carcinoma.一种与肾透明细胞癌肿瘤微环境相关的新型预后标志物
Front Oncol. 2022 Jul 4;12:912155. doi: 10.3389/fonc.2022.912155. eCollection 2022.
8
Bioinformatic Analysis of the Expression and Clinical Significance of the DNA Replication Regulator MCM Complex in Bladder Cancer.DNA复制调节因子MCM复合物在膀胱癌中的表达及临床意义的生物信息学分析
Int J Gen Med. 2022 Jun 7;15:5465-5485. doi: 10.2147/IJGM.S368573. eCollection 2022.
9
MCM2-7 in Clear Cell Renal Cell Carcinoma: MCM7 Promotes Tumor Cell Proliferation.MCM2 - 7在透明细胞肾细胞癌中的作用：MCM7促进肿瘤细胞增殖。
Front Oncol. 2021 Dec 21;11:782755. doi: 10.3389/fonc.2021.782755. eCollection 2021.
10
Systemic Analysis of the DNA Replication Regulator MCM Complex in Ovarian Cancer and Its Prognostic Value.卵巢癌中DNA复制调节因子MCM复合体的系统分析及其预后价值
Front Oncol. 2021 Jun 9;11:681261. doi: 10.3389/fonc.2021.681261. eCollection 2021.
本文引用的文献
1
Minichromosome Maintenance Complex (MCM) Genes Profiling and MCM2 Protein Expression in Cervical Cancer Development.微小染色体维持复合体（MCM）基因谱分析及MCM2蛋白表达在宫颈癌发生发展中的作用
Asian Pac J Cancer Prev. 2019 Oct 1;20(10):3043-3049. doi: 10.31557/APJCP.2019.20.10.3043.
2
Stage-specific conditional survival in renal cell carcinoma after nephrectomy.肾细胞癌肾切除术后特定阶段的条件生存。
Urol Oncol. 2020 Jan;38(1):6.e1-6.e7. doi: 10.1016/j.urolonc.2019.08.011. Epub 2019 Sep 12.
3
MCM2, MCM4, and MCM6 in Breast Cancer: Clinical Utility in Diagnosis and Prognosis.MCM2、MCM4 和 MCM6 在乳腺癌中的作用：诊断和预后的临床应用。
Neoplasia. 2019 Oct;21(10):1015-1035. doi: 10.1016/j.neo.2019.07.011. Epub 2019 Aug 30.
4
MCM5 promotes tumour proliferation and correlates with the progression and prognosis of renal cell carcinoma.MCM5 促进肿瘤增殖，并与肾细胞癌的进展和预后相关。
Int Urol Nephrol. 2019 Sep;51(9):1517-1526. doi: 10.1007/s11255-019-02169-3. Epub 2019 Jun 12.
5
Prognostic relevance of topoisomerase II α and minichromosome maintenance protein 6 expression in colorectal cancer.在结直肠癌中，拓扑异构酶 IIα 和微小染色体维持蛋白 6 的表达与预后的相关性。
BMC Cancer. 2019 May 9;19(1):429. doi: 10.1186/s12885-019-5631-3.
6
Prognostic value of minichromosome maintenance mRNA expression in early-stage pancreatic ductal adenocarcinoma patients after pancreaticoduodenectomy.微小染色体维持蛋白mRNA表达在胰十二指肠切除术后早期胰腺导管腺癌患者中的预后价值
Cancer Manag Res. 2018 Sep 5;10:3255-3271. doi: 10.2147/CMAR.S171293. eCollection 2018.
7
Expression of Minichromosome Maintenance Proteins (MCM) and Cancer Prognosis: A meta-analysis.微小染色体维持蛋白（MCM）的表达与癌症预后：一项荟萃分析。
J Cancer. 2018 Apr 6;9(8):1518-1526. doi: 10.7150/jca.22691. eCollection 2018.
8
MCM6 promotes metastasis of hepatocellular carcinoma via MEK/ERK pathway and serves as a novel serum biomarker for early recurrence.MCM6 通过 MEK/ERK 通路促进肝细胞癌的转移，并作为早期复发的新型血清生物标志物。
J Exp Clin Cancer Res. 2018 Jan 22;37(1):10. doi: 10.1186/s13046-017-0669-z.
9
Minichromosome maintenance complex component 6 (MCM6) expression correlates with histological grade and survival in endometrioid endometrial adenocarcinoma.MCM6 在子宫内膜样腺癌中的表达与组织学分级和生存相关。
Virchows Arch. 2018 Apr;472(4):623-633. doi: 10.1007/s00428-017-2278-9. Epub 2017 Dec 14.
10
Expression of minichromosome maintenance genes in renal cell carcinoma.微小染色体维持基因在肾细胞癌中的表达。
Cancer Manag Res. 2017 Nov 15;9:637-647. doi: 10.2147/CMAR.S146528. eCollection 2017.
Zotero 插件